ML
CGTX icon

McAdam LLC’s Cognition Therapeutics CGTX Stock Holding History

McAdam LLC’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.2K Sell
64,553
-5,400
-8% -$6.39K ﹤0.01% 505
2026
Q1 		$53.1K Sell
69,953
-4,156
-6% -$4.84K ﹤0.01% 438
2025
Q4 		$100K Buy
74,109
+2,034
+3% +$3.3K ﹤0.01% 411
2025
Q3 		$97.3K Buy
+72,075
New +$98.3K ﹤0.01% 389

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

McAdam LLC's CGTX Position: Q2 2026 in Review

McAdam LLC reduced its Cognition Therapeutics (CGTX) stake by 7.7% in Q2 2026, selling an estimated $6.39K and leaving 64,553 shares worth $74.2K. The position accounts for ﹤0.01% of the portfolio, ranked #505.

McAdam LLC first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $100K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • McAdam LLC held 64,553 shares of Cognition Therapeutics worth $74.2K as of Q2 2026.
  • McAdam LLC sold 5,400 Cognition Therapeutics shares in Q2 2026, an estimated $6.39K.
  • Cognition Therapeutics made up ﹤0.01% of McAdam LLC's portfolio in Q2 2026, its #505 holding.
  • McAdam LLC first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • McAdam LLC's Cognition Therapeutics position peaked at $100K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on McAdam LLC's 13F filing for Q2 2026, filed 4 Aug 2026.